GlassScriptPhysician profile
James M Miller
NPI 1831415231
$1,826.24
in general payments reported to CMS, 2019-2025
25 companies · $603 in 2025
The $603 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.21 · 2021: $13.52 · 2022: $458 · 2023: $454 · 2024: $255 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.74 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $252.30 | 2023-2025 | |
| Coopersurgical, INC. | $239.09 | 2022-2025 | Mara Console, Paragard T 380a |
| Sage Therapeutics, LLC | $208.44 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $118.83 | 2023-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $110.41 | 2023-2025 | Myfembree, Gemtesa |
| Duchesnay USA Incorporated | $61.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.96 | 2022-2023 | |
| Hologic Sales and Service, LLC | $44.81 | 2024-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Meditrina | $34.04 | 2025 | |
| Exeltis, USA INC. | $32.07 | 2022-2025 | Slynd |
| Myovant Sciences INC. | $29.91 | 2022 | |
| Organon LLC | $29.15 | 2022 | |
| Astellas Pharma US INC | $28.73 | 2025 | Veozah |
| Ethicon US, LLC | $25.38 | 2024 | Enseal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $25.27 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.02 | 2025 | Qelbree |
| Pacira Pharmaceuticals Incorporated | $22.53 | 2023 | Exparel |
| Evofem Biosciences, INC. | $18.52 | 2023 | Phexxi |
| Biogen, INC. | $18.36 | 2023 | Spinraza |
| Millicent US INC | $17.84 | 2025 | Femlyv, Intrarosa |
| Sanofi Pasteur INC. | $16.04 | 2024 | |
| Urovant Sciences INC | $14.26 | 2022 | |
| Smith+Nephew, INC. | $13.89 | 2025 | Pico 14 |
| Pfizer INC. | $13.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.